辅助放疗在颅内恶性脑膜瘤中的作用:基于全国数据库的分析
本研究利用台湾癌症登记库识别2007至2018年诊断的恶性脑膜瘤患者,比较术后辅助放疗与未放疗者的生存结局。共纳入204例患者,94例(46%)接受辅助放疗;放疗组中位总生存3.0年,未放疗组2.0年(p=0.001),但Kaplan-Meier曲线log-rank检验显示两组总生存无显著差异(p=0.999)。校正年龄、性别、组织学亚型、治疗、合并症及Charlson合并症指数后,辅助放疗未带来生存获益(HR=0.87;95%CI:0.6‒1.26);仅较高合并症评分与不良生存相关(HR=2.03,95%CI:1.04‒3.94)。
要点
- 204例恶性脑膜瘤中94例(46%)接受辅助放疗,两组基线特征分布相似。
- 放疗组中位总生存3.0年,未放疗组2.0年(p=0.001),但log-rank检验无显著差异(p=0.999)。
- 校正混杂因素后辅助放疗未带来生存获益(HR=0.87;95%CI:0.6‒1.26)。
核心结论
- 这项基于人群的回顾性分析提示,放疗在恶性脑膜瘤中的作用仍不明确,并强调需要随机临床试验来评估辅助放疗的实用性。
研究设计与样本
- 基于台湾癌症登记库的回顾性人群分析,识别2007至2018年诊断的恶性脑膜瘤患者,并通过死亡登记库进行随访。
- 共纳入204例患者,其中94例(46%)接受辅助放疗,比较放疗与未放疗患者的生存。
- 评估的潜在混杂因素包括年龄、性别、合并症及Charlson合并症指数(CCI)。
主要发现
- 两组性别分布(p=0.53)、平均年龄(p=0.33)、组织学亚型(p=0.13)及CCI(p=0.62)相似。
- 恶性脑膜瘤预后差,中位总生存为2.4年。
- 放疗组中位总生存3.0年(四分位距[IQR] [1.4-6.1]),未放疗组2.0年(IQR [0.5-3.9])(p=0.001)。
- Kaplan-Meier曲线log-rank检验显示两组总生存无显著差异(p=0.999)。
- 校正年龄组、性别、组织学亚型、治疗、合并症及CCI后,辅助放疗未带来生存获益(HR=0.87;95%CI:0.6‒1.26);仅较高合并症评分与不良生存相关(HR=2.03,95%CI:1.04‒3.94)。
临床怎么用
- 原文未据此给出推荐,作者结论指出放疗的作用仍不明确并强调需要随机临床试验评估辅助放疗的实用性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to examine the effect of postoperative radiotherapy on survival outcomes in patients with malignant meningiomas. METHODS: We identified patients with malignant meningioma diagnosed between 2007 and 2018 using the Taiwan Cancer Registry and followed them up using the death registry. Survival was compared between patients with and without adjuvant radiotherapy. The potential confounding factors evaluated in this study included age, sex, comorbidities, and the Charlson Comorbidity Index (CCI). RESULTS: The analysis included 204 patients; 94 (46%) received adjuvant radiotherapy. The two groups had similar sex distributions (p = 0.53), mean age (p = 0.33), histologic subtype (p = 0.13), and CCI (p = 0.62). The prognosis of malignant meningioma was poor, with a median overall survival (OS) of 2.4 years. The median OS was 3.0 years (interquartile range (IQR) [1.4-6.1], and 2.0 years (IQR [0.5-3.9]) in the radiotherapy and non-radiotherapy groups, respectively (p = 0.001). However, Kaplan-Meier curves with the log-rank test showed no significant difference in OS between the two groups (p = 0.999). Controlling for age group, sex, histologic subtype, treatment, comorbidities, and CCI, adjuvant radiotherapy did not impart a survival benefit (hazard ratio [HR] = 0.87; 95% confidence interval [CI]: 0.6‒1.26); however, only factor of higher comorbidity score (HR = 2.03, 95%CI: 1.04‒3.94) was associated with unfavorable survival. CONCLUSION: This population-based retrospective analysis suggests that the role of radiotherapy remains unclear and underscores the need for randomized clinical trials to assess the usefulness of adjuvant radiotherapy in malignant meningioma.
引用
- Ho CH, Shieh LT, Lin CH, et al. The role of adjuvant radiotherapy for intracranial malignant meningiomas: analysis of a nationwide database. J Neurooncol. 2024. PMID: 38814405. doi:10.1007/s11060-024-04720-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。